{"id":614145,"date":"2026-09-18T01:57:35","date_gmt":"2026-09-18T01:57:35","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/614145\/ace-therapeutics-expands-pulmonary-hypertension-model-development-services-for-preclinical-drug-research.html"},"modified":"2026-09-18T01:57:35","modified_gmt":"2026-09-18T01:57:35","slug":"ace-therapeutics-expands-pulmonary-hypertension-model-development-services-for-preclinical-drug-research","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/614145\/ace-therapeutics-expands-pulmonary-hypertension-model-development-services-for-preclinical-drug-research.html","title":{"rendered":"Ace Therapeutics Expands Pulmonary Hypertension Model Development Services for Preclinical Drug Research"},"content":{"rendered":"
\"Ace<\/a><\/div>\n
<\/div>\n

New York, US – September 17, 2026 – <\/strong>Ace Therapeutics, a specialized preclinical contract research organization (CRO) supporting respiratory disease research, offers customized pulmonary hypertension (PH) model development services<\/a> to support academic and biopharmaceutical research programs investigating novel therapeutic approaches for pulmonary hypertension. Its service portfolio combines disease model development with hemodynamic, histopathological, molecular, pharmacological, and other preclinical assessments to generate disease-relevant data for drug discovery and development.<\/p>\n

Pulmonary hypertension is a clinically heterogeneous and multifactorial condition characterized by elevated pressure within the pulmonary circulation and progressive changes in the pulmonary vasculature and, in many cases, the right ventricle. Because its underlying mechanisms and pathological features can vary across disease settings, appropriate in vivo<\/em> models are important for evaluating therapeutic efficacy and investigating disease mechanisms. Ace Therapeutics provides a range of established and customized rodent PH models designed to reproduce selected pathological features of pulmonary hypertension according to specific research objectives.<\/p>\n

Ace Therapeutics offers multiple rodent models of pulmonary hypertension<\/a>, including chemically induced, hypoxia-based, and genetically modified systems in rats and mice. Available models include monocrotaline (MCT)-induced PH, chronic hypoxia-induced PH, SU5416 plus hypoxia (SuHx)-induced severe pulmonary vascular remodeling, bleomycin-associated PH in pulmonary fibrosis models, and genetically modified models such as BMPR2 mutant lines for mechanistic research. Additional experimental factors, including high-fat diet or age-related conditions, can be incorporated when appropriate to investigate metabolic or age-associated influences on pulmonary vascular disease. Surgical approaches such as pulmonary artery banding may also be considered for studies focused on right ventricular pressure overload, remodeling, or failure.<\/p>\n

Beyond animal model development, Ace Therapeutics provides integrated preclinical assessments aligned with pulmonary hypertension research endpoints. Its service scope includes in vivo<\/em> monitoring and hemodynamic measurements such as right ventricular systolic pressure (RVSP), mean pulmonary arterial pressure (mPAP), and echocardiography; histopathology and morphometric evaluation of pulmonary vascular remodeling, right ventricular hypertrophy using the Fulton index, immunohistochemistry, and pulmonary fibrosis; as well as molecular and biochemical analyses using ELISA, qPCR, RNA-seq, Western blotting, and oxidative stress biomarkers. PK\/PD studies, dose-range finding, tolerability assessment, and combination therapy evaluation can also be incorporated into broader preclinical programs according to study requirements.<\/p>\n

Ace Therapeutics follows a customized model development workflow beginning with scientific consultation to identify the animal model and study design most appropriate for the research objectives. The process includes tailored protocol development covering animal numbers, dosing schedules, study timepoints, and relevant endpoints; model establishment and, where appropriate, pilot characterization to assess baseline features and reproducibility; full preclinical study execution with progress updates; and comprehensive reporting with raw data, statistical analyses, histological images, and scientific interpretation. Defined quality-control procedures are applied throughout the study process to support data consistency, traceability, and integrity.<\/p>\n

“Selecting an appropriate pulmonary hypertension model is an important consideration when evaluating therapeutic candidates with different mechanisms of action,” said a senior scientist at Ace Therapeutics. “Our customized approach allows study designs and disease models to be aligned with specific research questions, while integrated hemodynamic, pathological, and molecular assessments provide a broader view of treatment-related effects.”<\/p>\n

Ace Therapeutics’ combined capabilities in custom pulmonary hypertension model development<\/a> and integrated preclinical assessment allow researchers to select or develop disease-relevant models based on study objectives, mechanisms of action, and desired efficacy endpoints. By combining model development with downstream pharmacological and analytical support, the company supports comprehensive preclinical research programs for pulmonary hypertension.<\/p>\n

About Ace Therapeutics<\/p>\n

Ace Therapeutics is a specialized preclinical contract research organization (CRO) providing customized disease models and integrated preclinical research services across multiple therapeutic areas. The company supports pharmaceutical and biotechnology research programs through services including efficacy evaluation, pharmacokinetic and pharmacodynamic analysis, toxicology studies, biomarker research, histopathology, and disease model development. Its respiratory disease research capabilities include customized animal models and analytical workflows designed to support the preclinical investigation of pulmonary hypertension and other respiratory disorders.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Ace Therapeutics
Contact Person:<\/strong> Daisy Mostert
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.acetherapeutics.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

New York, US – September 17, 2026 – Ace Therapeutics, a specialized preclinical contract research organization (CRO) supporting respiratory disease research, offers customized pulmonary hypertension (PH) model development services to<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/614145"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=614145"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/614145\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=614145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=614145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=614145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}